Amphotericin B liposomal
Contents
Description
Amphotericin B liposomal is a lipid formulation of the polyene antifungal amphotericin B. It is used for treatment of severe systemic fungal infections including fungal myositis caused by various fungi such as Aspergillus, Candida, and Mucorales species. The liposomal formulation reduces nephrotoxicity compared to conventional amphotericin B while maintaining antifungal efficacy.
Indications & Therapeutic Use
Fungal myositis, invasive aspergillosis, candidiasis, mucormycosis, cryptococcal meningitis
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Amphotericin B liposomal — GNH India
74 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Amphotericin B liposomal |
| Brands | 1 brand available |
| Active Ingredient | Amphotericin B |
| Drug Class | Fungal myositis |
| Manufacturer | Gilead Sciences |
| Dosage Forms | IV infusion, 50mg vial for reconstitution |
| Medical Code | J02AA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 8 countries |